Clinical Leader - Helping clinical research professionals connect and collaborate

Healthcare, cooperation, teamwork-GettyImages-2191354117

How Acquiring Sponsors Can Keep Post-Acquisition Clinical Operations Running Smoothly

When acquiring another company, the acquiring sponsor must preserve operational continuity across active trials while integrating new assets, teams, technologies, vendors, and decision structures. Leila Cupersmith explains how.

GUEST COLUMNISTS

What's The Role Of HEOR For A Clinical Researcher? A Perspective From ISPOR 2026
On the heels of ISPOR 2026, discover what relevancy HEOR has in the world of clinical operations.
Why Tolerability Will Drive The Next Wave Of Obesity Treatments
For the next generation of obesity medicines, enhancing how patients experience therapy will inform discovery and development efforts and may ultimately determine long-term success.
Why Cell And Gene Therapy Has Not Reached More Patients — And Why Clinical Operations Is The Bridge
Safety Is The Mantra In Kivu Bioscience's ADC Trials For Solid Tumors
Kivu Bioscience CEO Mohit Trikha, Ph.D., contends that safer ADCs enable higher effective dosing and could elicit a better response in solid tumors. In this Q&A, he also discusses how parallel trial execution, global site strategy, and stakeholder collaboration support rapid, data-driven development.
Taking On Patient Recruitment From Another Angle — The Payer
Medzown CEO Jennifer Carter, MD, discusses the challenge of patient recruitment and how coalescing around clinical care data might be a better “in” for recruitment.
Clinical Trial Ads, Informed Consent, And Half-Hearted Regulation
Should informed consent really start with clinical trials ads? And if not, why do IRBs need to be involved in their approval? Paul Ivisin unravels the tangled web of IRBs, regulators, and clinical trial advertisements.
FDA's HALO Platform And Elsa 4.0: Five Critical Risks For Sponsors
Discover five critical risks created by HALO's architecture and Elsa 4.0's expanded capabilities. Then, learn how to implement practical safeguards sponsors to implement immediately.
Biotech Ecosystem Helps Advance A New Approach To Inflammation Into Trials
BioAegis Therapeutics CEO Susan Levinson, Ph.D., talks about the role of partner and regulatory support in bringing their investigational immunotherapy into the clinic.

CLINICAL TRIAL WHITE PAPERS

Understanding How To Build And Leverage A DSMB Statistical Plan
Get an overview of the essential components involved in providing independent statistical center support for a data safety monitoring board (DSMB), also known as a data monitoring committee (DMC).

Bringing Clinical Trials To Everyone's Backyard
1/10/2025

Learn how bringing clinical trials to any community around the world is not only possible but also increases patient access and reach and improves recruitment and retention.
The Impact Of High Inflation And The Great Resignation On Clinical Site Budgeting
10/30/2024

The twin pressures of inflation and attrition prolong negotiations between sponsors and clinical sites, stalling drug development. Sponsors need up-to-date, reliable benchmark data to negotiate fair market value budgets.
How Adaptive Design Accelerates Early‑Phase NSCLC Development
5/22/2026

Adaptive trial designs and an adaptive mindset enable non-small cell lung cancer (NSCLC) sponsors to optimize dose, respond to evolving expectations, and accelerate early‑phase development.
10 Clinical Research Practices That Feel Like Compliance (But Aren't)
3/24/2026

Many clinical research routines are driven by habit, not regulation. This guide clears up 10 common misconceptions to streamline workflows and reduce unnecessary admin work.
Combination Therapy Dose Optimization In Oncology Trials
3/30/2026

Optimize dose selection in oncology trials by moving beyond toxicity limits. Use advanced modeling and benefit-risk analysis to improve efficacy and meet modern regulatory standards.

More Clinical Trial White Papers

CLINICAL TRIAL APP NOTES & CASE STUDIES

The Perfect Solution For Recruitment, Retention, And ROI
8/15/2024

See how Citeline Connect was deployed to advance enrollment six months ahead of schedule for a sponsor’s Phase IV atopic dermatitis trial and build a community of engaged patients.
FastChain®: A Solution For Made-To-Order Gene Replacement Therapy Study
3/12/2026

Adopt a demand-led clinical supply strategy to reduce waste, optimize limited product supply, and accelerate patient access across global clinical trials.
Enhancing Investigator Training And Communication During COVID-19
6/26/2024

Centralizing all trial-related information, enabling seamless interaction and global team coordination through Scout Academy.
Top 10 Global Pharma Company Dramatically Improves Site Payments In Drive To Become Sponsor Of Choice
10/30/2024

See how a pharma company reduced investigator payment cycle time by 55% while decreasing their own administrative burden by 90% in this metrics-rich case study.
Drug-Drug Interaction Study On A Novel Cardiovascular Medication
9/17/2024

Learn how Altasciences leveraged its expertise to design, recruit, and conduct complex DDI studies, assessing pharmacokinetic and pharmacodynamic impacts of co-administered drugs.
Optimizing EDC Strategy And Data Collection for a Rare Disease Trial
6/11/2025

Explore how Veristat created a forward-looking roadmap for EDC and CRFs integration for a small biotech sponsor, ensuring a future-ready data ecosystem without overcomplicating current operations.

More Clinical Trial App Notes & Case Studies

NEWSLETTER ARCHIVE

More Newsletters

RECRUITMENT AND DIVERSITY

This section includes some helpful resources regarding patient recruitment and diversity in clinical trials, including this link to the FDA's guidance on diversity action plans.

Lessons In Pivoting From A Clinical Trial Launch In Uganda

Gates MRI researchers share how they navigated supply chain challenges, an Ebola outbreak, and evolving regional malaria vaccination strategies to successfully execute a malaria clinical trial in Uganda.
Expanding Access To Cell Therapy Trials Beyond AMCs And Into The Community

CEO Paul J. Hastings discusses Nkarta's decision to bring outpatient dosing into the community setting, including how it communicated with the FDA on safety and how the changes will improve patient access.
Taking On Patient Recruitment From Another Angle — The Payer

Medzown CEO Jennifer Carter, MD, discusses the challenge of patient recruitment and how coalescing around clinical care data might be a better “in” for recruitment.

FOCUS ON PATIENTS

Expanding Access To Cell Therapy Trials Beyond AMCs And Into The Community

CEO Paul J. Hastings discusses Nkarta's decision to bring outpatient dosing into the community setting, including how it communicated with the FDA on safety and how the changes will improve patient access.
Why Tolerability Will Drive The Next Wave Of Obesity Treatments

For the next generation of obesity medicines, enhancing how patients experience therapy will inform discovery and development efforts and may ultimately determine long-term success.
Designing Trials Patients Can Actually Complete: Lessons From The SWIFT Deep TMS Study

Being time conscious and attuned to patient needs are two contributing factors to trials that recruit and retain patients for the duration.